Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donafenib Combined with Capecitabine for Adjuvant Treatment of High-Risk Biliary Tract Cancer
NCT06685289Phase 2Recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of donafenib in biliary tract cancer (BTC), sponsored by Jiangsu Provincial People's Hospital. Started Nov 2024; status: recruiting.
02
Drugs
donafenib
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06685289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06685289.